Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 11/20 | 0.64 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.64 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL771716 | 0.78 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP2A6 | |
| SCHEMBL2360805 | 0.78 | CYP19A1 (0.61) | CYP11B1CYP11B2CYP19A1LOXL2CYP2A6 | |
| Hydrochloric Acid SCHEMBL8307735 | 0.77 | CYP11B1 (0.97) | CYP11B1CYP11B2CYP19A1CYP2A6 | |
| Hydrazine SCHEMBL28019549 | 0.75 | CYP11B1 (0.94) | CYP11B1CYP11B2CYP19A1CYP2A6 | |
| SCHEMBL5541647 | 0.74 | CYP19A1 (0.61) | CYP11B1CYP11B2CYP19A1CYP2A6 | |
| SCHEMBL7976423 | 0.74 | CYP19A1 (0.53) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL11372093 | 0.74 | CYP19A1 (0.59) | CYP11B1CYP11B2CYP19A1CYP2A6 | |
| SCHEMBL13946675 | 0.72 | CYP19A1 (0.60) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL2222933 | 0.72 | CYP19A1 (0.41) | CYP11B1CYP11B2CYP19A1CYP2A6 | |
| SCHEMBL14549033 | 0.72 | CYP19A1 (0.49) | CYP11B1CYP11B2CYP19A1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190997-A1 | Process for the Preparation of Letrozole | CADILA HEALTHCARE LIMITED (IN) | 2010-07-29 | — | — | US | claimed |
| EP-1945618-A2 | PROCESS FOR THE PREPARATION OF LETROZOLE | CADILA HEALTHCARE LTD. (IN) | 2008-07-23 | — | — | EP | claimed |
| WO-2007054964-A2 | PROCESS FOR THE PREPARATION OF LETROZOLE | CADILA HEALTHCARE LIMITED (IN) | 2007-05-18 | — | — | WO | claimed |
| US-9150524-B2 | Pure intermediate | GENERICS [UK] LIMITED (GB) | 2015-10-06 | — | — | US | disclosed |
| US-20130203826-A1 | Pure Intermediate | GENERICS [UK] LIMITED (GB) | 2013-08-08 | — | — | US | disclosed |
| US-8198460-B2 | Process for preparation of letrozole and its intermediates | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2012-06-12 | — | — | US | disclosed |
| US-8198460-B2 | Process for preparation of letrozole and its intermediates | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2012-06-12 | — | — | US | disclosed |
| WO-2012025762-A2 | PURE INTERMEDIATE | GENERICS [UK] LIMITED (GB) | 2012-03-01 | — | — | WO | disclosed |
| EP-2212301-B1 | AN IMPROVED PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES | FRESENIUS KABI ONCOLOGY LTD (IN) | 2012-02-29 | — | — | EP | disclosed |
| US-8003804-B2 | Synthesis of 4-[1-(4-cyano phenyl)-(1,2,4-triazol-1-yl)methyl] benzonitrile and 4-[1-(1H-1,2,4-triazol-1-yl)methylene benzonitrile intermediate | CIPLA LIMITED (IN) | 2011-08-23 | — | — | US | disclosed |
| US-8003804-B2 | Synthesis of 4-[1-(4-cyano phenyl)-(1,2,4-triazol-1-yl)methyl] benzonitrile and 4-[1-(1H-1,2,4-triazol-1-yl)methylene benzonitrile intermediate | CIPLA LIMITED (IN) | 2011-08-23 | — | — | US | disclosed |
| US-20070112203-A1 | The impurity isoletrozole is more rapidly oxidized to 4,4'-dicyanobenzophenone than Letrozole, which can be seperated by crystallization to yield highly purified letrozole | CHEMAGIS LTD. (IL) | 2007-05-17 | — | — | US | disclosed |
| US-20070112203-A1 | The impurity isoletrozole is more rapidly oxidized to 4,4'-dicyanobenzophenone than Letrozole, which can be seperated by crystallization to yield highly purified letrozole | CHEMAGIS LTD. (IL) | 2007-05-17 | — | — | US | disclosed |
| WO-2007039912-A1 | A ONE POT PROCESS FOR THE PREPARATION OF 4-[1-CYANOPHENYL)-1-(1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE | USV LIMITED (IN) | 2007-04-12 | — | — | WO | disclosed |
| US-20070066831-A1 | Process for the preparation of letrozole | SICOR, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070066831-A1 | Process for the preparation of letrozole | SICOR, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20060128775-A1 | Regiospecific process for the preparation of 4-[1- (4-cyanophenyl)-1-(1,2,4-triazol-1-yl) methyl] benzonitrile | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2006-06-15 | — | — | US | disclosed |
| EP-1594850-A2 | REGIOSPECIFIC PROCESS FOR THE PREPARATION OF 4- 1- (4-CYANOPHENYL)-1-(1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE | Sun Pharmaceuticals Industries Ltd. (IN) | 2005-11-16 | — | — | EP | disclosed |
| US-20050209294-A1 | Process for producing 4-(1H-1,2,4-triazol-1-ylmethyl)benzonitrile | M/S. IND-SWIFT LABORATORIES LIMITED (IN) | 2005-09-22 | — | — | US | disclosed |
| WO-2004076409-A2 | REGIOSPECIFIC PROCESS FOR THE PREPARATION OF 4-[1- (4-CYANOPHENYL)-1-(1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066831-A1 | Process for the preparation of letrozole | CYP19A1, CYP4B1, CYP3A4 | CYP11B1 14/4885CYP11B2 44/4885CYP19A1 1/4885 |
| US-20070112203-A1 | The impurity isoletrozole is more rapidly oxidized to 4,4'-dicyanobenzophenone than Letrozole, which can be seperated by crystallization to yield highly purified letrozole | CYP19A1, HSD17B11, SHBG | CYP11B1 27/4885CYP11B2 44/4885CYP19A1 1/4885 |
| US-20130203826-A1 | Pure Intermediate | CYP19A1, CYP11A1, CYP11B1 | CYP11B1 3/4885CYP11B2 4/4885CYP19A1 1/4885 |
| US-20060128775-A1 | Regiospecific process for the preparation of 4-[1- (4-cyanophenyl)-1-(1,2,4-triazol-1-yl) methyl] benzonitrile | CYP4B1, KDM4B, CYP3A4 | CYP11B1 857/4885CYP11B2 1266/4885CYP19A1 1741/4885 |
| US-20050209294-A1 | Process for producing 4-(1H-1,2,4-triazol-1-ylmethyl)benzonitrile | CYP19A1, NR5A1, KCNK4 | CYP11B1 164/4885CYP11B2 306/4885CYP19A1 1/4885 |
| US-20100190997-A1 | Process for the Preparation of Letrozole | CYP19A1, CYP11A1, HSD17B11 | CYP11B1 5/4885CYP11B2 13/4885CYP19A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.